CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 14 enrolled
Drug / intervention
Ranolazine 500 MG +1 moredrug
Likely dose
Ranolazine 500 MGfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03472950
NCT03472950Phase 2Completed
CompareCT.gov

Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis

University of Kansas Medical Center·interventional·Posted Mar 21, 2018·Updated Dec 9, 2024

In Brief

A Phase 2 clinical trial evaluating Ranolazine 500 MG and Ranolazine 1000 MG for ALS. Completed, enrolled 14 participants across 1 site.

Detailed Summary

The purpose of this research study is to evaluate the safety and effectiveness of Ranolazine, and how well it is tolerated in patients with Amyotrophic Lateral Sclerosis (ALS). Ranolazine is an FDA approved drug that is used for decreasing chest pain.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsALS
CountriesUnited States
CollaboratorsGilead Sciences

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMar 21, 2018
Enrollment StartJun 11, 2018
Primary CompletionDec 11, 2020
Study CompletionDec 9, 2022
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 8.3 years ago

Interventions

Ranolazine 500 MGdrug

Ranolazine is an FDA approved drug for angina (ongoing chest pain or pressure that is felt when the heart does not get enough oxygen).

Ranolazine 1000 MGdrug

Ranolazine is an FDA approved drug for angina (ongoing chest pain or pressure that is felt when the heart does not get enough oxygen).